Ryme Medical TLD Pilot Study

计划入组 60 人 · 首次发布于 2023 年 8 月 1 日

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

计划入组 12 人 · 首次发布于 2018 年 1 月 2 日

Evaluation of the Safety and Efficacy of TLD in Patients with COPD

计划入组 464 人 · 首次发布于 2018 年 8 月 20 日

TLD-1433

TLD-1433-apo-transferrin

Ruvidar

RIKEN VITAMIN CO., LTD.

Japan

Gossamer Bio

United States

TTD INTERNATIONAL PTY LTD

Australia

Theralase Expands Bladder Cancer Clinical Trial with New Sites and Promising Phase II Data

Theralase Reports 65.2% Complete Response Rate in Phase II Bladder Cancer Study, Plans NDA Filing in 3Q2026

Theralase's Light-Activated Bladder Cancer Therapy Shows Promising Results in Phase II Trial